• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ovarian Cancer Drug Pipeline Update 2014 Product Image

Ovarian Cancer Drug Pipeline Update 2014

  • Published: March 2014
  • Region: Global
  • Bioseeker

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing and pipeline drugs.
There are today 242 companies plus partners developing 335 drugs targeting ovarian cancer in development. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 94 drugs. Ovarian Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 253 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 247 out of the 250 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 66 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug READ MORE >



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos